Alcon: Berenberg still a buyer, but cuts target price
(CercleFinance.com) - Berenberg maintains its buy rating on the share of Novartis' former opthalmological subsidiary Novartis, while cutting its corresponding target price from 69 Swiss francs to 65 Swiss francs.
In comments sent to its clients, the German broker explains that after an investment phase concentrated on its R&D and commercial capacities, the group is now poised to deliver "attractive" and "defensive" growth with significantly higher margins over the medium term.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
In comments sent to its clients, the German broker explains that after an investment phase concentrated on its R&D and commercial capacities, the group is now poised to deliver "attractive" and "defensive" growth with significantly higher margins over the medium term.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.